What ABA Therapy Buyers Actually Look For (And What Kills Deals)

After walking ABA therapy owners through acquisition processes with private equity platforms, strategic consolidators, and independent sponsors, a pattern becomes clear: the things buyers say they want in the first meeting are rarely the things that actually kill or close deals in diligence. This post lays out what ABA buyers actually prioritize, what they discount quietly but significantly, and the specific issues we see kill otherwise promising transactions.

What Do ABA Therapy Buyers Look For?

ABA therapy buyers look for three things above all else: clinical team stability, clean authorization-backed revenue, and a business that can operate independent of the owner. Everything else — growth story, geographic footprint, technology, brand — is secondary to those three.

This isn’t a marketing position; it’s how buyers actually underwrite. When a PE-backed ABA platform models an acquisition, it’s pricing the probability that your BCBAs will still be there in two years, the durability of your authorized-hour pipeline, and the operational risk of transitioning away from the founder. Everything the diligence team digs into is ultimately a proxy for one of those three questions.

The Criteria That Actually Matter to ABA Buyers

The following are the specific criteria we see buyers weight most heavily in ABA therapy acquisition decisions, ranked by typical valuation impact:

• BCBA retention and tenure. Average BCBA tenure, voluntary turnover rate, and the percentage of BCBAs on W-2 (not 1099) are scrutinized closely. Buyers pay premiums for stable clinical teams and discount aggressively for high turnover or contractor-heavy models.
• Authorization pipeline depth and utilization. Buyers want to see a healthy backlog of authorized hours combined with consistent weekly utilization. A gap between authorized and delivered hours signals either operational friction or demand softness — both discount factors.
• Payer mix diversification. A balanced blend of commercial insurance, TRICARE, and Medicaid typically trades better than single-payer or Medicaid-heavy practices. Heavy Medicaid concentration (above 70%) meaningfully compresses multiples.
• Supervision ratios that meet or exceed standards. BCBA-to-RBT ratios are examined against state requirements and payer expectations. Thin ratios raise clinical quality and compliance concerns.
• Center-based operational leverage. Center-based ABA generally trades at higher multiples than in-home-heavy models because of fixed-cost leverage and supervision efficiency. Hybrid models can trade well if the in-home book is geographically clustered.
• Owner independence. If the practice can’t run for 30–60 days without the owner, buyers either walk or discount heavily. This is the single biggest avoidable discount in ABA M&A.
• Clean clinical documentation and audit history. Session notes, treatment plans, and prior authorization documentation are reviewed in clinical diligence. Gaps are treated as compliance risk and priced accordingly.
• EBITDA margin consistency. Buyers want stable margins in the 15%–25% range for well-run center-based practices. Wild margin swings raise questions about underlying operations.
• Multi-location scalability. Single-center practices trade at lower multiples than 2–5 location platforms because buyers pay for demonstrated operational repeatability.

What Buyers Say They Want vs. What Actually Moves the Number

There’s a meaningful gap between what buyers emphasize in initial conversations and what actually drives their final price.

The items on the left aren’t unimportant — they influence whether a buyer shows up at all — but they rarely change the price. The items on the right are where deals actually get priced.

What Kills ABA Deals in Diligence?

Most ABA deals that fall apart in diligence fail for one of six specific reasons. Almost all of them are preventable if the issue is identified 6–18 months before marketing.

• BCBA resignations during the process. Nothing collapses a deal faster than a senior clinician leaving after the LOI is signed. Buyers re-price immediately. Retention bonuses and careful internal disclosure management are the primary defenses.
• Quality of earnings surprises. When a buyer’s QofE provider strips out aggressive or undocumented add-backs, the adjusted EBITDA can drop 10%–20% or more — often a full turn or more of multiple value.
• Pending or recent payer audits. An active or recently closed payer audit, especially with clawback findings, raises the entire risk profile of the practice. Disclosure upfront is always better than discovery in diligence.
• Authorization pipeline weakness. If the trailing 60 days of authorized hours show declining utilization or a shrinking backlog, buyers read it as leading-indicator revenue weakness — even when trailing EBITDA looks fine.
• Credentialing problems surfacing late. Expired BCBA credentialing, stalled new-provider enrollment, or payer contract issues discovered in diligence raise questions about operational discipline and create immediate revenue risk.
• Owner dependency becoming obvious. When buyers spend time in the business and realize the owner still handles all key payer relationships, intake decisions, or clinical supervision personally, the discount grows — sometimes enough to renegotiate the deal.

How to Position Your ABA Practice to Buyers

Build the business buyers actually want to underwrite, not the business you think they want to see. That means investing preparation time in clinical team stability, W-2 conversion, clean financial records, compliance housekeeping, and management layer depth — not in rebrand projects or growth stories.

For a deeper breakdown of how an ABA sale process actually works, see our sell an ABA therapy business page.

Frequently Asked Questions

Learn more about how we represent ABA therapy sellers.